Lumenis Gains FDA Clearance to Market New Selecta® Family of Lasers and Introduces Eight New Products at the 2005 American Academy of Ophthalmology Annual Meeting

Yokneam, Israel, October 13, 2005 – Lumenis^® Ltd. (LUME.PK), a global developer, manufacturer and seller of laser and light-based devices for medical, aesthetic, ophthalmic, dental and veterinary applications, announced today that it has received FDA clearance to market the new Selecta® family of lasers and will introduce a total of eight new ophthalmic lasers and delivery devices on October 15th at the American Academy of Ophthalmology (AAO) Annual Meeting in Chicago, Illinois.

Avner Raz, Lumenis President and Chief Executive Officer, stated “This accomplishment represents the first time in Lumenis history that a market introduction of this magnitude has occurred in the ophthalmic arena. This industry-leading achievement stems from Lumenis’ 40-year history of technology research and development in Ophthalmology. In 1970, we were the first company to introduce a laser in this field. Since then, we have followed with a series of additional sight-preserving milestones, including the “first” laser photocoagulator, laser indirect ophthalmoscope, multicolor photocoagulator, photodynamic therapy laser, selective laser trabeculoplasty system and solid state multicolor laser.”

“As previously announced, Lumenis recently received the 2005 Technology Leadership Award from Frost & Sullivan. At this year’s AAO Meeting, we simply continue this long-standing tradition as we proudly showcase the newest additions to our existing and already full line of ophthalmic lasers – a new and complete set of ophthalmic laser solutions. Our Selecta family of lasers for the complete ophthalmic practice offers it all – from ultimate simplicity, to choice of therapy with maximum flexibility. Our new laser delivery devices are specifically designed to provide superior visibility and performance, as well as improve physician comfort during procedures,” said Avner Raz.

New Product Introductions

• Selecta^® 1064 nm Nd:YAG Base Platform – An essential tool for ophthalmologists treating the anterior segment of the eye, as in the elimination of secondary cataracts and performing peripheral iridotomies. The Selecta platform offers multiple upgrade options that are simple and straightforward.
• Selecta^® Duo – Adding the S-Link LaserLink™ to the Selecta platform creates the Selecta^® Duo, a versatile Nd:YAG and 532 nm Photocoagulator combination laser that extends treatment capabilities to procedures involving both the anterior segment and posterior pole of the eye.
• Selecta^® Duet ™ – A Q-switched frequency-doubled 532 nm laser combined with the Selecta platform YAG laser expands treatment options to include Selective Laser Trabeculoplasty (SLT) for open-angle glaucoma.
• Selecta^® Trio – The pinnacle in the family, combining the Nd:YAG, diode-pumped solid-state (DPSS) 532 Photocoagulator and Q-switched frequency-doubled 532nm laser (SLT) and offering maximum flexibility in choice of therapy. 
• Novus^® 3000¹ – A fully-integrated and powerful 532 nm Operating Room Photocoagulator with reliable DPSS technology and simplified operation using a touch screen interface and remote control. This unit comes standard with built-in storage for a laser indirect ophthalmoscope (LIO), remote control, foot switch and other accessories.
• Lumenis^® 1000 Integrated Slit Lamp – Fully-integrated biomicroscope slit lamp laser delivery system, complete with built-in LaserLink, parallel optics, magnification changer, micromanipulator and multicolor automatic eye safety filters.
• Lumenis^® 950 Slit Lamp – Zeiss-style diagnostic slit lamp biomicroscope with parallel optics and offering a choice of automatic or fixed eye safety filters for multiple wavelengths.
• Coaxial Multicolor LIO – World’s first coaxial multicolor LIO provides precise laser delivery with repeatable outcomes, as well as maximum treatment options and physician safety.

Ophthalmologists attending the 2005 AAO meeting and seeking ultimate simplicity, maximum flexibility, choice of therapy and the complete operating room solution will have access to Lumenis’ new technology in AAO booth 3219, October 15 th through October 18 th.

^{1 Pending FDA clearance}

About the American Academy of Ophthalmology and 2005 Annual Meeting

The American Academy of Ophthalmology is the largest national membership association of ophthalmologists, medical doctors who provide comprehensive eye care, including medical, surgical and optical care. More than 90 percent of practicing U.S. ophthalmologists are Academy members, and the Academy has more than 7,000 international members. The Academy's 109th Annual Meeting from October 15 to 18 will be in Chicago, IL, at McCormick Place. The 2005 Annual Meeting program will highlight how technology advances are improving patient care. For more information about the AAO and Annual Meeting, log onto: http://www.aao.org/annual_meeting

Lumenis is a global developer, manufacturer and seller of laser and light-based devices for medical, aesthetic, ophthalmic, dental and veterinary applications. The Company offers a wide range of products along with extensive product support systems including training, education and service. Lumenis invests heavily in research and development to maintain and enhance its leading industry position. The Company holds numerous patents worldwide on its technologies. For more information about Lumenis and its products, log onto www.lumenis.com.


Contact:

Lauri Hanover, CFO
1-866-232-6803
+972-4-959-9122

The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties. The Company's actual results could differ materially from those anticipated in the forward looking statements based on a variety of factors, including, among others: uncertainties with respect to market acceptance of the Company's products, the implementation and outcome of its Turnaround Plan, obtaining regulatory approvals for new products or for the sale of existing products in new markets and enforcement of intellectual property rights; risks associated with competition and competitive pricing pressures, economic conditions generally, the Company's international operations and the Company's ability to integrate its operations with those of acquired businesses; the outcome of the Securities and Exchange Commission investigation and several securities class action lawsuits to which the Company is subject and the outcome of the investigation conducted by the Audit Committee; uncertainties relating to the Company’s continuing liquidity; and other risks detailed from time to time in the reports filed by Lumenis with the SEC, including its annual report on Form 10-K and quarterly reports on Form 10-Q.